E pili ana iā C-CAR031

He lāʻau lapaʻau autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) ʻo C-CAR031, ke aʻo ʻia nei no ka mālama ʻana i ka HCC.

Ua hōʻike waha ʻia ka holomua o ka noiʻi o C-CAR031 i ka hepatocellular carcinoma (HCC) ma ka hālāwai makahiki o ka American Society of Clinical Oncology (ASCO) i mālama ʻia ma Chicago i ka makahiki 2024.

Nā Hana: ʻO ka hoʻokolohua hoʻonui nui mua loa i ke kanaka, hāmama ka lepili, e hoʻohana ana i kahi hoʻolālā titration wikiwiki me i3+3. ʻO nā poʻe HCC holomua GPC3+ i hāʻule i nā lāʻau lapaʻau ʻōnaehana ≥ 1 laina i loaʻa i hoʻokahi infusion iv o C-CAR031 ma hope o ka lymphodepletion maʻamau. ʻO nā hopena mua ka palekana a me ka hoʻomanawanui, ʻo nā mea ʻē aʻe e komo pū me ka pharmacokinetics a me ka pono mua. Ua helu ʻia nā hanana ʻino (AEs) e CTCAE 5.0, a ua loiloi ʻia ka cytokine release syndrome (CRS) / immune effector cell-associated neurotoxicity syndrome (ICANS) e like me nā pae hoʻohālikelike ASTCT 2019. Ua loiloi ʻia ka pane pahuhopu e ka mea noiʻi e like me RECIST 1.1.

Nā Hualoaʻa: Ma Ianuali 5, 2024, he 24 mau pts i loaʻa i ka hoʻokomo ʻana o C-CAR031 ma 4 mau pae mahele (DLs). Loaʻa i nā pts āpau ke kahua BCLC C HCC, 83.3% (20/24) i loaʻa ka metastasis extrahepatic. ʻO ka helu waena o nā laina mua o ka lāʻau lapaʻau he 3.5 (pae 1-6), 23 (95.8%) pts i loaʻa i nā ICI (nā mea pale i ka nānā ʻana o ka pale) a me nā TKI (nā mea pale tyrosine kinase). Hiki ke loiloi ʻia nā pts āpau no ka palekana. ʻAʻohe ʻawaʻawa palena mahele a ua ʻike ʻia nā ICANS. Ua ʻike ʻia ʻo CRS ma 22 (91.7%) pts me 1 wale nō (4.2%) papa (G) 3 CRS. ʻO nā ≥G3 AE maʻamau loa he lymphocytopenia (100%), neutropenia (70.8%), thrombocytopenia (37.5%) a me ka hoʻokiʻekiʻe ʻana o ka transaminase (16.7%). Hoʻokahi pt (4.2%) i loaʻa i ka G4 myelosuppression a me 1 pt (4.2%) i loaʻa i ka G3 interstitial pneumonitis ma DL4 i hoʻokumu ʻia e G3 CRS. Ua hoʻohuli ʻia nā AE āpau. Hiki ke loiloi ʻia he 22 pts no ka pono. Ua ʻike ʻia ka hōʻemi ʻana o ka tumor ma 90.9% pts, ʻaʻole wale ma nā ʻeha intrahepatic akā ʻo nā mea extrahepatic me ka hōʻemi waena o 44.0% (pae, 3.4%-94.4%). ʻO ka helu kaohi maʻi he 90.9% a ʻo ka helu pane pahuhopu (ORR) he 50.0% no nā pts o nā DL āpau. Ma DL4, ʻo ka ORR he 57.1%.

Nā hopena: Ua hōʻike ke aʻo ʻana i kahi ʻano palekana e hiki ke hoʻokele ʻia a me ka hoʻoikaika ʻana i ka hana anti-tumor o C-CAR031 i nā poʻe maʻi HCC holomua i mālama nui ʻia.

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com

Nā Kuhikuhi

1.https://www.prnewswire.com/news-releases/abelzeta-announces-clinical-data-showing-preliminary-anti-tumor-activity-for-c-car031-an-armored-autologous-gpc3-car-t-in-patients-with-advanced-hepatocellular-carcinoma-at-asco-annual-meeting-2024-302162941.html

2.https://www.abelzeta.com/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/

3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019

4.ASCO-2024-IR-Presentation.pdf (astrazeneca.com)